PSC Clinical Trials Opportunity

Chemomab's SPRING Study is recruiting volunteers to take part at nine different study sites across England and Scotland now.

Where are the study sites? · Addenbrooke's Hospital, Cambridge · John Radcliffe Hospital, Oxford · King's College Hospital, London · Norfolk & Norwich University Hospital, Norwich · Queens Medical Centre, Nottingham · Royal Free Hospital, London · Glasgow Royal Inrmary · Derriford Hospital, Plymouth · St James's University Hospital, Leeds

Am I suitable for the trial? Every clinical trial sets out strict rules dening who can and can't take part. Find out if you are likely to be eligible in the Key Trial Information check out this link: https://www.pscsupport.org.uk/nd-psc-research-studies

My hospital is not running the SPRING study but I think I am suitable. What should I do? If you think you are eligible (suitable) and you want to take part but your hospital is not running the trial, it is still possible to take part. Talk to your PSC doctor or contact the nearest study site to you. Some people switch hospitals temporarily for the duration of the clinical trial so that their PSC care and clinical trial study visits are at the same hospital; or they have a 'shared care' agreement whereby they still see their regular hospital doctor but also the PSC specialist who is running the clinical trial. Most PSC doctors will be supportive and coordinate this for you.

What is the SPRING Study investigating? The SPRING study is investigating CM-101, that can block the actions of a small protein called CCL24. CCL24 is involved in cell “communication” that helps regulate inammation and is involved in the development of brosis (scarring). CCL24 is found in higher concentrations in PSC patients than the general population.

CM-101 is a monoclonal antibody, created by Chemomab. It can block the actions of CCL24 and thus its role in the development of inammation and brosis. CM-101 was tested in several animal models, including the MDR2 knockout mice (mice that have severe brosis in the bile ducts and liver, eventually developing cirrhosis). These tests showed that CM-101 signicantly reduced liver brosis, and markers that indicate the presence of inammation in the bile ducts.

Martine Walmsley (Chair) PSC Support Helpline/ofce: 01235 25 35 45 Email: hello@pscsupport.org.uk